Univariable and multivariable Cox regression analyses for the association of podoplanin expression with risk of future VTE
| Risk factor . | Univariable HR (95% CI) . | P . | Multivariable HR (95% CI) . | P . |
|---|---|---|---|---|
| Age, per 10-y increase | 1.04 (0.81-1.35) | .744 | 0.84 (0.63-1.31) | .255 |
| Female sex | 0.50 (0.21-1.16) | .106 | 0.52 (0.22-1.21) | .130 |
| Tumor grade | ||||
| WHO grade IV | Reference | Reference | Reference | Reference |
| Others | 0.41 (0.16-1.08) | .072 | 0.54 (0.18-1.61) | .271 |
| Podoplanin expression | ||||
| Negative (−) | Reference | Reference | Reference | Reference |
| Low (+) | 2.48 (0.76-8.09) | .131 | 2.44 (0.73-8.17) | .148 |
| Medium (++) | 3.64 (1.09-12.17) | .036 | 3.28 (0.91-11.75) | .068 |
| High (+++) | 5.75 (1.71-19.27) | .005 | 5.71 (1.52-21.36) | .010 |
| Risk factor . | Univariable HR (95% CI) . | P . | Multivariable HR (95% CI) . | P . |
|---|---|---|---|---|
| Age, per 10-y increase | 1.04 (0.81-1.35) | .744 | 0.84 (0.63-1.31) | .255 |
| Female sex | 0.50 (0.21-1.16) | .106 | 0.52 (0.22-1.21) | .130 |
| Tumor grade | ||||
| WHO grade IV | Reference | Reference | Reference | Reference |
| Others | 0.41 (0.16-1.08) | .072 | 0.54 (0.18-1.61) | .271 |
| Podoplanin expression | ||||
| Negative (−) | Reference | Reference | Reference | Reference |
| Low (+) | 2.48 (0.76-8.09) | .131 | 2.44 (0.73-8.17) | .148 |
| Medium (++) | 3.64 (1.09-12.17) | .036 | 3.28 (0.91-11.75) | .068 |
| High (+++) | 5.75 (1.71-19.27) | .005 | 5.71 (1.52-21.36) | .010 |
In multivariable analysis, adjustment for all other factors listed was performed.